Harmony Biosciences (NASDAQ:HRMY) Cut to Hold at Zacks Research

Zacks Research lowered shares of Harmony Biosciences (NASDAQ:HRMY) from a strong-buy rating to a hold rating in a research report released on Wednesday,Zacks.com reports.

A number of other research analysts have also recently issued reports on HRMY. Wall Street Zen raised Harmony Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Bank of America cut their price target on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a report on Wednesday. Needham & Company LLC decreased their price objective on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Harmony Biosciences in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 target price for the company. in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.67.

Harmony Biosciences Stock Performance

NASDAQ HRMY opened at $28.54 on Wednesday. Harmony Biosciences has a twelve month low of $25.52 and a twelve month high of $40.87. The company has a quick ratio of 3.72, a current ratio of 3.60 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.65 billion, a P/E ratio of 10.53, a PEG ratio of 0.36 and a beta of 0.84. The company’s 50-day simple moving average is $36.01 and its 200 day simple moving average is $34.07.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a net margin of 18.29% and a return on equity of 19.86%. The company had revenue of $243.78 million for the quarter, compared to analyst estimates of $240.04 million. During the same period in the previous year, the firm posted $0.85 earnings per share. The firm’s revenue for the quarter was up 21.1% compared to the same quarter last year. As a group, research analysts forecast that Harmony Biosciences will post 2.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Sandip Kapadia sold 3,746 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $37.15, for a total transaction of $139,163.90. Following the completion of the transaction, the chief financial officer directly owned 24,521 shares in the company, valued at approximately $910,955.15. The trade was a 13.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total transaction of $1,040,172.63. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 50,640 shares of company stock valued at $1,932,256. 23.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Harmony Biosciences

Several large investors have recently bought and sold shares of HRMY. EverSource Wealth Advisors LLC boosted its position in shares of Harmony Biosciences by 589.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock worth $28,000 after purchasing an additional 643 shares in the last quarter. Allworth Financial LP raised its stake in Harmony Biosciences by 286.7% during the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after buying an additional 602 shares during the period. Leonteq Securities AG bought a new position in Harmony Biosciences during the fourth quarter worth about $30,000. Parkside Financial Bank & Trust grew its stake in Harmony Biosciences by 4,185.2% in the second quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock valued at $37,000 after acquiring an additional 1,130 shares during the period. Finally, National Bank of Canada FI acquired a new position in Harmony Biosciences in the third quarter valued at about $40,000. Institutional investors own 86.23% of the company’s stock.

More Harmony Biosciences News

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $55 price target and published a long-range FY2030 EPS projection (which reinforces an upbeat long-term thesis), supporting upside potential despite near-term cuts. HC Wainwright research on HRMY
• Neutral Sentiment: An aggregate coverage note reported HRMY has an average analyst rating of “Moderate Buy,” indicating mixed consensus sentiment across the sell-side. This tempers the impact of individual downgrades but leaves the stock sensitive to further model changes. Average analyst rating report
• Negative Sentiment: Zacks Research downgraded HRMY from “strong-buy” to “hold,” reducing near-term buy-side conviction and likely contributing to selling pressure. Zacks downgrade
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” citing patent trial developments — a direct legal/intellectual property risk that can materially affect exclusivity and future revenue, and is a key reason for today’s weakness. Truist downgrade after patent trial developments
• Negative Sentiment: HC Wainwright also lowered near-term EPS forecasts across Q1–Q4 2026 (multiple cuts to quarterly estimates), signaling weaker near-term profitability expectations that can pressure the stock until guidance or sales trends rebound. HC Wainwright EPS revision details

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.